ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-SIRPa Monoclonal Antibody DS-1103

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Daiichi Sankyo.

Furthest: phase 2, since Jul 28, 20262 company-led studies, 2 open or runningNext primary completion: May 31, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Daiichi Sankyo22 open or runningphase 2since Jul 28, 2026Mar 1, 2023May 31, 2029phase 1 · NCT05765851

Also a collaborator on its studies: AstraZeneca.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 1, 2023First study: phase 1 study in Advanced Solid TumorFirst studyNCT05765851 · 128 planned · United States, Canada, France and more
  2. Jul 28, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungPhase 2 reachedNCT07739966 · 400 planned · United States, Argentina, Austria and more

Ahead

  1. May 31, 2029Primary completion: phase 1 study in Advanced Solid TumorNCT05765851
  2. Jul 31, 2030Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07739966

TargetBeta

SIRPA →read by rule
“An immunoglobulin G4 (IgG4) monoclonal antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), ”NCIt, by rule

Other programs on SIRPA

ProgramCompanyFurthest phaseStudies
Anti-SIRPa Monoclonal Antibody BI 770371ruleBoehringer Ingelheimphase 24
Anti-SIRPalpha Monoclonal Antibody BYON4228rulebyondis-b-vphase 12

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07739966Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more2RecruitingJul 31, 2030400
NCT05765851Advanced Solid Tumor · United States, Canada, France and more1RecruitingMay 31, 2029128

How it is read

Names in the registry

  • “DS-1103a”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.